Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 32
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1551 | CHART | 9 | 00% | 0 | 9 | 2022–2024 |
| 1552 | CHEMPOLIS | 9 | 222.2% | 1 | 6 | 2022–2025 |
| 1553 | CHINA ALUMINUM INTERNATIONAL ENGINEERING | 9 | 00% | 0 | 9 | 2024–2026 |
| 1554 | CHINT LOW VOLTAGE ELECTRICAL TECHNOLOGY | 9 | 00% | 1 | 8 | 2023–2024 |
| 1555 | COMMONWEALTH FUSION SYSTEMS | 9 | 00% | 0 | 9 | 2024–2026 |
| 1556 | COSMO ARTIFICIAL INTELLIGENCE AI | 9 | 111.1% | 1 | 7 | 2022–2024 |
| 1557 | CRUNCHFISH DIGITAL CASH | 9 | 111.1% | 1 | 7 | 2022–2025 |
| 1558 | CUMMINS FILTRATION IP | 9 | 777.8% | 0 | 2 | 2020–2024 |
| 1559 | D E SHAW RESEARCH | 9 | 00% | 7 | 2 | 2022–2024 |
| 1560 | D3 BIO WUXI | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1561 | DAIICHI JITSUGYO VISWILL | 9 | 111.1% | 0 | 8 | 2020–2026 |
| 1562 | DAIKYO SEIKO | 9 | 222.2% | 1 | 6 | 2022–2024 |
| 1563 | DAVOL | 9 | 111.1% | 1 | 7 | 2022–2026 |
| 1564 | DECIBEL THERAPEUTICS | 9 | 00% | 0 | 9 | 2023–2025 |
| 1565 | DEEP RENDER | 9 | 00% | 1 | 8 | 2022–2025 |
| 1566 | DEUTSCHE TELEKOM | 9 | 111.1% | 0 | 8 | 2023–2025 |
| 1567 | DUKOSI | 9 | 00% | 0 | 9 | 2023–2026 |
| 1568 | ECOCEM MATERIALS | 9 | 00% | 0 | 9 | 2022–2025 |
| 1569 | ECP ENTWICKLUNGSGESELLSCHAFT MBH | 9 | 111.1% | 0 | 8 | 2021–2026 |
| 1570 | ENERGY VAULT | 9 | 00% | 1 | 8 | 2022–2024 |
| 1571 | EVELO BIOSCIENCES | 9 | 00% | 8 | 1 | 2022–2023 |
| 1572 | F I S FABBRICA ITALIANA SINTETICI | 9 | 333.3% | 0 | 6 | 2022–2025 |
| 1573 | FARADION | 9 | 00% | 0 | 9 | 2022–2026 |
| 1574 | FATE THERAPEUTICS | 9 | 00% | 0 | 9 | 2022–2024 |
| 1575 | FINA TECHNOLOGY | 9 | 222.2% | 0 | 7 | 2022–2025 |
| 1576 | FORSIGHT ROBOTICS | 9 | 00% | 0 | 9 | 2023–2025 |
| 1577 | G SENTHILNATHAN B R C I S T | 9 | 00% | 1 | 8 | 2022–2025 |
| 1578 | GACW | 9 | 111.1% | 0 | 8 | 2022–2024 |
| 1579 | GENSQUARE | 9 | 9100% | 0 | 0 | 2019–2019 |
| 1580 | GERRESHEIMER GLAS | 9 | 00% | 1 | 8 | 2022–2024 |
| 1581 | GOLDMAN SACHS | 9 | 222.2% | 1 | 6 | 2019–2025 |
| 1582 | GRADIANT | 9 | 00% | 1 | 8 | 2022–2026 |
| 1583 | H BNER KG | 9 | 555.6% | 0 | 4 | 2022–2024 |
| 1584 | HAISCO PHARMACEUTICAL GROUP | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1585 | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL | 9 | 111.1% | 0 | 8 | 2023–2025 |
| 1586 | HELLA KGAA | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1587 | HEMEX HEALTH | 9 | 444.4% | 0 | 5 | 2022–2025 |
| 1588 | HK INNO N | 9 | 222.2% | 0 | 7 | 2022–2025 |
| 1589 | HUBBELL | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1590 | HUTCHISON MEDIPHARMA | 9 | 00% | 0 | 9 | 2022–2023 |
| 1591 | IDEMIA IDENTITY SECURITY FRANCE | 9 | 333.3% | 1 | 5 | 2017–2024 |
| 1592 | ILDONG PHARMACEUTICAL | 9 | 222.2% | 4 | 3 | 2022–2024 |
| 1593 | INTELLECTUAL DISCOVERY | 9 | 111.1% | 0 | 8 | 2020–2025 |
| 1594 | INTRA CELLULAR THERAPIES | 9 | 111.1% | 0 | 8 | 2020–2025 |
| 1595 | IONIQA TECHNOLOGIES | 9 | 111.1% | 1 | 7 | 2022–2024 |
| 1596 | JAPAN TOBACCO | 9 | 00% | 0 | 9 | 2022–2025 |
| 1597 | JGC | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1598 | JOHNSON MATTHEY SHANGHAI CHEMICALS | 9 | 00% | 0 | 9 | 2022–2024 |
| 1599 | KALVISTA PHARMACEUTICALS | 9 | 00% | 6 | 3 | 2022–2025 |
| 1600 | KINGFAR INTERNATIONAL | 9 | 00% | 0 | 9 | 2024–2024 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →